阿里云首页 > 域名与网站 > 域名服务 > 域名信息查询(WHOIS) > 网站关键词查询结果

 

与 "positive" 相关网站域名


域名czmix.com的网站信息

域名wcee.net的网站信息

域名rometlimited.com的网站信息

域名sharpshape.com的网站信息

域名hmeet.com的网站信息

  • 网站标题

      Hmeet.com - STD Dating Site for People with Herpes and other STDs.
  • 网站关键字

       std   herpes   hsv   dating   site   singles   positive   hpv  
  • 网站描述

      Hmeet.com is a herpes dating site for STD singles to find someone to talk to,to laugh with and understands what you go through!

域名anttooling.com的网站信息

  • 网站标题

      rapid tooling and rapid prototype
  • 网站关键字

       rapid   tooling   injection   moulding   die   cast   positive   mold   moulding   tooling   mould  
  • 网站描述

      ANT is a company that major in making rapid tooling. We are in this area for several years, we can make all kinds of tooling, no matter for the plastic or metal, even tube and glasses, we are aim to satisfied with our clients with our excellent service

域名ppsc.com的网站信息

域名trastuzumab.info的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名trastuzumab.org的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名trastuzumab.biz的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名trastuzumab.net的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名trastuzumab.com的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名herceptin.info的网站信息

  • 网站标题

      HER2+ Breast Cancer Treatment with Herceptin® (trastuzumab)
  • 网站关键字

  • 网站描述

      Find information about Herceptin® (trastuzumab), a targeted therapy for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. Indications Adjuvant Breast Cancer Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-postive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC?TH” With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH” Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy) Patients are selected for therapy based on an FDA-approved test for Herceptin *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. Metastatic Breast Cancer Herceptin has 2 approved uses in metastatic breast cancer: Herceptin in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer Herceptin alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease Patients are selected for therapy based on an FDA-approved test for Herceptin Gastric Cancer Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Patients are selected for therapy based on an FDA-approved test for Herceptin. Important Patient Safety Information Possible Serious Side Effects With HERCEPTIN Not all people have serious side effects, but side effects with HERCEPTIN therapy are common. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. HERCEPTIN is not for everyone. Be sure to contact your doctor if you are experiencing any of the following: HEART PROBLEMS These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. INFUSION REACTIONS, including: Fever and chills Feeling sick to your stomach (nausea) Throwing up (vomiting) Pain (in some cases at tumor sites) Headache Dizziness Shortness of breath These signs usually happen within 24 hours after receiving HERCEPTIN. Be sure to contact your doctor if you: Are a woman who could become pregnant, or may be pregnant HERCEPTIN may result in the death of an unborn baby or birth defects. Contraception should be used while receiving HERCEPTIN and after your last dose of HERCEPTIN. If you are exposed to HERCEPTIN during pregnancy or within 7 months of becoming pregnant, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report HERCEPTIN exposure to Genentech at 1-888-835-2555. Have any signs of SEVERE LUNG PROBLEMS, including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Your doctor may check for signs of severe lung problems when he or she examines you. Have LOW WHITE BLOOD CELL COUNTS Low white blood cell counts can be life threatening. Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you. Side Effects Seen Most Often With HERCEPTIN Some patients receiving HERCEPTIN for breast cancer had the following side effects: Fever Feeling sick to your stomach (nausea) Throwing up (vomiting) Infusion reactions Diarrhea Infections Increased cough Headache Feeling tired Shortness of breath Rash Low white and red blood cell counts Muscle pain Some patients receiving HERCEPTIN for metastatic stomach cancer had the following side effects: Low white blood cell counts Diarrhea Feeling tired Low red blood cell counts Swelling of the mouth lining Weight loss Upper respiratory tract infections Fever Low platelet counts Swelling of the mucous membranes Swelling of the nose and throat Change in taste You should contact your doctor immediately if you have any of the side effects listed above. You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1–800–FDA–1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1–888–835–2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information, including Boxed WARNINGS.

域名phoenixindustrial.com的网站信息

域名dairymachinery.com的网站信息

域名sinoink.com的网站信息

  • 网站标题

      Offset Printing Ink, Web Offset Ink, Positive Ps Plate, Printing Materials Manufacturers and Suppliers - China Factory - Angel Chemicals
  • 网站关键字

       offset   printing   ink   web   offset   ink   positive   ps   plate   printing   materials   toner  
  • 网站描述

      Tianjin Angel Chemicals Group, established in 1949, is one of the biggest and oldest printing ink and printing chemicals manufacturers in China mainly producing various high quality sheeted and rotary inks as well as premium quality printing chemicals.

域名positivediscipline.biz的网站信息

域名qford.com的网站信息

域名choobon.com的网站信息

  • 网站标题

      Choobon Dogs Academy - Choobon Dogs Training Academy
  • 网站关键字

  • 网站描述

      Certified Professional Dog Trainer and Behavior Specialist at Choobon Dogs Academy, dog training in New York and New Jersey.

域名onlinekungfu.net的网站信息


免责声明:
本页面内容来源于他人发布于网络的公开信息,阿里云不负责其合法性、准确性判断,并不对使用该类信息的结果承担任何法律责任。同时,阿里云提示您审慎判断。


总共记录: 194条, 共10页, 第1页 [下一页]